Predicting Cancer's Recurrence:

How AI is Giving Doctors a Head Start

Paper written by:
Martina **Carlà**
Madeleine **Cremona**

HEPHAESTUS APPLIED ARTIFICIAL INTELLIGENCE ASSOCIATION

Over 90% of breast cancer patients survive five years after diagnosis. In the case of recurrence, that rate can drop to under 25%. A core challenge in oncology is that recurrence is largely unpredictable; dependent on subtle biological, molecular, and treatment-related factors. In fact, even after successful therapy, clinicians still struggle to identify which patients are at a higher risk of recurrence, leaving patients in a prolonged state of uncertainty.
However, with advancements in artificial intelligence in the field of medicine, early metastasis risk detection, prognosis, and optimized treatment predictions are becoming increasingly accurate. One such breakthrough is Yunfang Yu et al.'s 2025 Pharmacological Research study introducing an advanced 3D-MMR multimodal deep learning model which combines MRI imaging and clinical data to enable prediction of recurrence risk and guide adjuvant therapy in breast cancer patients. Conversely to traditional methods, this AI can detect patterns invisible to the human eye and is part of the larger movement toward predictive and personalized medicine.

In the management of breast cancer, an accurate estimate of the risk of relapse is pivotal in order to personalize therapy and follow-up. However, current imaging and clinical models often do not consider the biological hints that determine the recurrence of the illness.
Magnetic Resonance Imaging (MRI) provides in-depth structural and functional data, but its manual interpretation is not fully able to grasp the complex heterogeneity of cancer.
Standard clinical indicators only describe one part of the clinical picture. Therefore, a method that directly learns from imaging data and associates them with the clinical context is needed.
Deep learning allows this by identifying hidden spatial patterns that are correlated with recurrence, without requiring predefined rules. However, few studies have applied these methods specifically for the purpose of predicting disease-free survival (DFS) after surgery. To fill this gap, researchers have built a multimodal MRI-based AI system able to merge visual and clinical information in a unified recurrence-risk model: the 3D-MMR-model.

The 3D-MMR-model integrates MRI and clinical data through a three-stage deep learning pipeline. A modified 3D-UNet, a type of neural network that identifies and isolates the tumor region in MRI scans, performs automatic segmentation. The model analyzes T2-weighted MRI scans enhanced with contrast dye, which highlight differences in water content and blood flow within tissues. These images help the AI distinguish tumor boundaries and internal structures more clearly.
Once the tumor region is segmented, the model evaluates subtle visual patterns, such as shape, texture, and internal signals, that might indicate the aggressiveness of the tumor. The output is an MRI-based risk score estimating each patient's disease-free survival (DFS). The AI then merges imaging-based risk scores with key clinical factors, such as the tumor's stage and biological markers, to further enhance the personalization of the model.



The main impact of this model lies in the support it offers clinicians for making informed, personalized treatment decisions. By stratifying patients into high- and low-risk categories, clinicians can identify who would benefit from additional adjuvant therapy and who can safely avoid aggressive treatment.

In this optimization, high-risk patients can receive chemotherapy, hormone therapy, or HER2-targeted treatments, while low-risk patients benefit from fewer side effects, lower costs, and less overtreatment. These decisions are tailored to each patient's imaging and biological profile, increasing precision in prognosis and supporting "predictive prevention," where intervention occurs before relapse.

Beyond these benefits, several challenges remain. The study's results need validation across international, multi-ethnic cohorts, as its data were collected solely in Chinese institutions.

To move from lab to clinic, AI systems must meet the same standards of transparency, reproducibility, and safety as any medical device. Yet deep-learning models often act as

"black boxes," making their reasoning opaque. Techniques such as Grad-CAM visualizations can enhance transparency and improve validity.
Ethical issues also persist around privacy, accountability, and data bias. Nonetheless, with careful oversight and design, innovations like this can advance patient care and raise the overall standard of oncology.

In conclusion, Yunfang Yu et al.'s 3D-MMR model demonstrates how combining MRI imaging with artificial intelligence enables more accurate predictions of breast cancer recurrence, supporting clinicians in making treatment decisions. It marks a clear shift from descriptive to predictive, personalized care. Through AI-assisted clinical decision-making, such models could redefine oncology by providing patients with more precise prognoses and tailored therapies. Nevertheless, the insights offered by AI cannot replace human expertise, which ensure empathy, ethical judgment, and clinical nuance. As multimodal systems like this one continue to evolve, oncology may increasingly rely on algorithms as much as intuition, potentially saving lives before relapse occurs.

SOURCES:

- Yu Y, Ren W, Mao L, Ouyang W, Hu Q, Yao Q, Tan Y, He Z, Ban X, Hu H, Lin R, Wang Z, Chen Y, Wu Z, Chen K, Ouyang J, Li T, Zhang Z, Liu G, Chen X, Li Z, Duan X, Wang J, Yao H. MRI-based multimodal AI model enables prediction of recurrence risk and adjuvant therapy in breast cancer. Pharmacol Res. 2025 Jun;216:107765. doi: 10.1016/j.phrs.2025.107765. Epub 2025 May 7. PMID: 40345352.
- Figure reproduced from: Yu Y. et al. "MRI-based multimodal AI model enables prediction of recurrence risk and adjuvant therapy in breast cancer." Pharmacological Research 216 (2025): 107765. https://doi.org/10.1016/j.phrs.2025.107765. © Elsevier (CC BY 4.0)